Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 348-355

  Friso, Simonetta ^a   Udali, Silvia ^a   Guarini, Patrizia ^a   Pellegrini, Camilla ^a   Pattini, Patrizia ^a   Moruzzi, Sara ^a   Girelli, Domenico ^a   Pizzolo, Francesca ^a   Martinelli, Nicola ^a   Corrocher, Roberto ^a   Olivieri, Oliviero ^a   Choi, Sang Woon ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; GENOMIC DNA; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA METHYLATION; EARLY DIAGNOSIS; ENZYME BLOOD LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; GENOTYPE; GLOBAL DNA HYPOMETHYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL HISTORY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SMOKING HABIT; VITAMIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; DNA; DNA METHYLATION; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84876540906     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0859     Document Type: Article

References (29)

1. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-54. (Pubitemid 36278835)
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7. (Pubitemid 29070360)
3. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 1994;3:1487-95. (Pubitemid 24295497)
4. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006;310:251-74. (Pubitemid 47400293)
5. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-90. (Pubitemid 15117274)
6. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92. (Pubitemid 36444330)
7. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 2011;6:828-37.
8. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
9. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008;647:44-51.
10. Friso S, Choi SW. Gene-nutrient interactions and DNA methylation. J Nutr 2002;132:2382S-7S. (Pubitemid 34848112)
11. Friso S, Choi SW,Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002;99:5606-11. (Pubitemid 34411596)
12. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000;9:849-53. (Pubitemid 30660060)
13. Sohn KJ, Jang H, Campan M, Weisenberger DJ, Dickhout J, Wang YC, et al. The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int J Cancer 2009;124:1999-2005.
14. Zhang YJ, WuHC, Shen J, Ahsan H, Tsai WY, Yang HI, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007;13:2378-84. (Pubitemid 46698587)
15. Lim U, Flood A, Choi SW, Albanes D, Cross AJ, Schatzkin A, et al. Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology 2008;134:47-55. (Pubitemid 350309318)
16. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003;124:1240-8. (Pubitemid 36531800)
17. Hou L, Wang H, Sartori S,Gawron A, Lissowska J, Bollati V, et al. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer 2010;127:1866-74.
18. Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007;16:108-14. (Pubitemid 46174272)
19. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998;91:4158-63. (Pubitemid 28261978)
20. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000;343:774-80.
21. Friso S, Choi SW, Dolnikowski GG, Selhub J. A method to assess genomic DNA methylation using high-performance liquid chromatography/electrospray ionization mass spectrometry. Anal Chem 2002; 74:4526-31. (Pubitemid 35006443)
22. Friso S, Girelli D, Martinelli N, Olivieri O, Lotto V, Bozzini C, et al. Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. Am J Clin Nutr 2004;79:992-8. (Pubitemid 41095950)
23. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10:111-3.
24. Woo HD, Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS ONE 2012;7:e34615.
25. Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, et al. LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer 2012;130:1151-9.
26. Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res 2010;16:1682-9.
27. Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a casecontrol study. Lancet Oncol 2008;9:359-66.
28. Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 2009;30:1889-97.
29. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57: 1098-102. (Pubitemid 27138608)